Drugs by Condition

Atrial Fibrillation Medications

Definition of Atrial Fibrillation: A condition where there is disorganised electrical conduction in the atria, resulting in ineffective pumping of blood into the ventricle.

Acronym: AF

Drugs (by generic name) associated with Atrial Fibrillation

The following drugs and medications are in some way related to, or used in the treatment of Atrial Fibrillation. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-conditions

Drug Name ( View by: Brand \| Generic )	Reviews	Ratings
propafenone systemic (Pro, More...) class: antiarrhythmic agents, group I antiarrhythmics	9 review(s)	Rate It!	8.8
diltiazem systemic (Pro, More...) class: calcium channel blocking agents, group IV antiarrhythmics	7 review(s)	Rate It!	8.5
flecainide systemic (Pro, More...) class: antiarrhythmic agents, group I antiarrhythmics	13 review(s)	Rate It!	8.1
digoxin systemic (Pro, More...) class: group V antiarrhythmics, inotropic agents	2 review(s)	Rate It!	8.0
metoprolol systemic (Pro, More...) class: beta-adrenergic blocking agents, cardioselective beta blockers	4 review(s)	Rate It!	7.7
sotalol systemic (Pro, More...) class: beta-adrenergic blocking agents, group III antiarrhythmics, non-cardioselective beta blockers	4 review(s)	Rate It!	7.0
carvedilol systemic (Pro, More...) class: beta-adrenergic blocking agents, non-cardioselective beta blockers	1 review(s)	Rate It!	6.0
dronedarone systemic (Pro, More...) class: antiarrhythmic agents, group III antiarrhythmics	0 review(s)	Rate It!	1.0
esmolol systemic (Pro, More...) class: beta-adrenergic blocking agents, cardioselective beta blockers, group II antiarrhythmics	0 review(s)	Not rated - Be the first
ibutilide systemic (Pro, More...) class: antiarrhythmic agents, group III antiarrhythmics	0 review(s)	Not rated - Be the first
clonidine systemic (Pro, More...) class: antiadrenergic agents, centrally acting	0 review(s)	Not rated - Be the first

Atrial Fibrillation Medications in the Pipeline

Kynapid (vernakalant)

August 12, 2009 - Additional Clinical Trial to be Conducted for Kynapid Under FDA Special Protocol Agreement
October 9, 2008 - Cardiome Provides Kynapid Regulatory Update
August 11, 2008 - Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For Kynapid
January 22, 2008 - Cardiome And Astellas Announce Kynapid Regulatory Update
December 12, 2007 - FDA Advisory Committee Recommends Approval of Kynapid for Acute Atrial Fibrillation
August 30, 2007 - Cardiome And Astellas Announce Regulatory Extension
February 19, 2007 - Cardiome And Astellas Announce Acceptance Of NDA For Review
December 18, 2006 - Cardiome and Astellas Pharma US, Inc. Announce Re-Submission of NDA for Vernakalant (IV)
May 31, 2006 - Cardiome Announces Refusal to File Decision By the FDA
March 31, 2006 - New Drug Application Submitted For RSD1235

Pulzium (tedisamil)

December 13, 2007 - Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
September 26, 2007 - Solvay Pharmaceuticals, Inc. Announces FDA Extension of Tedisamil PDUFA Date
April 25, 2007 - Solvay Pharmaceuticals Files Tedisamil, a New Cardiometabolic Product for the Treatment of Atrial Fibrillation and Atrial Flutter

Latest Atrial Fibrillation Blog Post

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
- Pharmacokinetic Analysis of Atrial Fibrillation Study May Explain Bleeding Rate Difference between Once-Daily and Twice-Daily Dosing Regimens with Same Total Exposure of Factor Xa Inhibitor - BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of...

View all Atrial Fibrillation blog posts.